SCHEMBL4658408

SCHEMBL4658408

COC(=O)c1cc(NC(=O)CCc2ccc(OCCCCCc3ccccc3)cc2)ccc1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.51
LMNA P02545 2/20 0.51
KMT2A Q03164 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
FFAR1 O14842 2/20 0.51
ALDH1A1 P00352 2/20 0.51
HPGD P15428 1/20 0.51
RAB9A P51151 2/20 0.49
LTA4H P09960 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
KDM4E B2RXH2 3/20 0.48
CNR1 P21554 1/20 0.48
CNR2 P34972 1/20 0.48
S1PR1 P21453 2/20 0.47
NPC1 O15118 1/20 0.47
S1PR3 Q99500 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4657178 0.91 FFAR1 (0.54) MEN1KMT2ASMN1; SMN2FFAR1RAB9A
SCHEMBL4659396 0.91 FFAR1 (0.54) FFAR1ALDH1A1HPGDRAB9ALTA4H
SCHEMBL4657896 0.91 FFAR1 (0.54) MEN1KMT2ASMN1; SMN2FFAR1RAB9A
SCHEMBL4656898 0.91 FFAR1 (0.54) FFAR1ALDH1A1HPGDRAB9ALTA4H
SCHEMBL4658183 0.90 FFAR1 (0.55) MEN1KMT2ASMN1; SMN2FFAR1ALDH1A1
SCHEMBL4657187 0.90 FFAR1 (0.55) MEN1KMT2ASMN1; SMN2FFAR1ALDH1A1
SCHEMBL4659021 0.89 FFAR1 (0.52) KMT2AFFAR1ALDH1A1HPGDRAB9A
SCHEMBL4659193 0.89 FFAR1 (0.52) FFAR1RAB9ALTA4HS1PR1NPC1
SCHEMBL4657303 0.89 MEN1 (0.46) MEN1LMNAKMT2ASMN1; SMN2ALDH1A1
SCHEMBL4658368 0.89 MEN1 (0.46) MEN1LMNAKMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1391199-B1 CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO (JP) 2008-12-10 EP disclosed
US-20070088027-A1 Carboxylic acid derivatives and pharmaceutical compositions comprising the same as an active ingredient ONO PHARMACEUTICAL CO., LTD. 2007-04-19 US disclosed
US-20070088027-A1 Carboxylic acid derivatives and pharmaceutical compositions comprising the same as an active ingredient ONO PHARMACEUTICAL CO., LTD. 2007-04-19 US disclosed
US-7179817-B2 Carboxylic acid derivatives and drugs containing the same as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2007-02-20 US disclosed
US-7179817-B2 Carboxylic acid derivatives and drugs containing the same as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2007-02-20 US disclosed
US-20040224941-A1 Carboxylic acid derivatives and drugs containing the same as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-11 US disclosed
EP-1391199-A1 CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-02-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070088027-A1 Carboxylic acid derivatives and pharmaceutical compositions comprising the same as an active ingredient EDF1, FFAR1, EDNRA MEN1 1748/4885LMNA 2826/4885KMT2A 4772/4885
US-20040224941-A1 Carboxylic acid derivatives and drugs containing the same as the active ingredient EDF1, FFAR1, VCAM1 MEN1 1352/4885LMNA 3030/4885KMT2A 4829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.